GENUS PLC financials
GENUS PLC
Country: GB Reporting currency: GBP Latest annual report: 2025-06-30
LEI:
54930022EOITNKSIGH56 Financial statements
(GBP, as reported — unscaled; 105 line items across 3 annual periods)
| Line item | 2025 | 2024 | 2023 |
|---|---|---|---|
| Income statement | |||
| Revenue | £672.8M | £668.8M | — |
| Depreciation & amortisation | £5.6M | £5.8M | — |
| Operating profit (EBIT) | £42.4M | £6.4M | — |
| Net finance income / (cost) | -£18.8M | -£18.3M | — |
| Finance costs | £21.4M | £22.2M | — |
| Profit before tax | £28.5M | £5.5M | — |
| Income tax expense | £9.2M | £3.1M | — |
| Profit for the year | £19.3M | £2.4M | — |
| — attributable to owners | £19.3M | £7.9M | — |
| — attributable to NCI | £0 | -£5.5M | — |
| Total comprehensive income | -£23.8M | -£17.8M | — |
| Per share | |||
| Basic EPS | £0.29 | £0.12 | — |
| Diluted EPS | £0.29 | £0.12 | — |
| Free cash flow / share | £0.81 | £0.74 | — |
| Cash flow statement | |||
| Net cash from operating activities | £67.2M | £29.8M | — |
| Net cash from investing activities | -£13.8M | -£19.3M | — |
| Purchase of PP&E (capex) | £13.4M | £14.8M | — |
| Purchase of intangibles | £5.2M | £9.9M | — |
| Net cash from financing activities | -£46.6M | -£2.8M | — |
| Dividends paid | £21.1M | £21.0M | — |
| Proceeds from borrowings | £152.8M | £140.4M | — |
| Repayments of borrowings | £158.2M | £108.5M | — |
| Lease liability payments | £14.1M | £13.7M | — |
| Net change in cash | £6.8M | £7.7M | — |
| Balance sheet | |||
| Total assets | £899.0M | £987.8M | £966.4M |
| Non-current assets | £644.6M | £716.7M | £707.4M |
| Property, plant & equipment | £160.3M | £182.0M | £164.4M |
| Intangible assets & goodwill | £102.8M | £110.3M | £107.8M |
| Current assets | £254.4M | £271.1M | £259.0M |
| Inventories | £46.2M | £57.1M | £61.3M |
| Trade & other receivables | £119.2M | £135.2M | £132.1M |
| Cash & equivalents | £48.0M | £42.5M | £36.3M |
| Total equity | £476.0M | £513.5M | £536.8M |
| — attributable to owners | £476.1M | £517.8M | £544.5M |
| Non-controlling interests | -£100.0K | -£4.3M | -£7.7M |
| Non-current liabilities | £291.7M | £323.7M | £282.4M |
| Long-term borrowings | £215.9M | £228.2M | £196.0M |
| Lease liabilities (non-current) | £33.8M | £44.1M | £21.9M |
| Current liabilities | £131.3M | £150.6M | £147.2M |
| Short-term borrowings | £2.9M | £4.9M | £4.2M |
| Lease liabilities (current) | £13.3M | £14.0M | £10.0M |
| Trade & other payables | £107.7M | £123.2M | £122.0M |
| Deferred tax liabilities | £25.8M | £33.7M | £40.5M |
| Derived metrics | |||
| Free cash flow | £53.8M | £15.0M | — |
| Operating margin | 6.3% | 1.0% | — |
| Net margin | 2.9% | 0.4% | — |
| Return on equity | 4.1% | 0.5% | — |
| Cash conversion ratio | 3.48× | 12.42× | — |
| Capex coverage | 5.01× | 2.01× | — |
| Other reported items | |||
| Cash Flows From Losing Control of Subsidiaries Or Other Businesses Classified As Investing Activities | £0 | £5.1M | — |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | £2.4M | £0 | — |
| Comprehensive Income Attributable To Noncontrolling Interests | -£200.0K | -£5.5M | — |
| Comprehensive Income Attributable To Owners of Parent | -£23.6M | -£12.3M | — |
| Current Biological Assets | £34.7M | £32.3M | £23.8M |
| Current Derivative Financial Assets | £100.0K | £1.9M | £1.5M |
| Current Derivative Financial Liabilities | £2.2M | £1.7M | £1.8M |
| Current Provisions | £400.0K | £1.0M | £1.8M |
| Current Tax Assets | £6.2M | £2.1M | £4.0M |
| Current Tax Liabilities | £2.2M | £5.2M | £7.4M |
| Deferred Tax Assets | £30.9M | £28.1M | £16.5M |
| Dividends Paid To Noncontrolling Interests Classified As Financing Activities | £100.0K | £0 | — |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners Per Share | £0.22 | — | — |
| Dividends Received From Investments Accounted For Using Equity Method Classified As Investing Activities | £6.1M | £4.7M | — |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -£1.3M | -£1.5M | — |
| Expense From Sharebased Payment Transactions With Employees | £6.9M | £7.0M | — |
| Finance Income | £2.6M | £3.9M | — |
| Gains Losses On Fair Value Adjustment Biological Assets | -£13.3M | -£23.2M | — |
| Impairment Loss Recognised In Profit Or Loss Goodwill | £1.5M | £0 | — |
| Income Tax Relating To Components of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss | £5.1M | £100.0K | — |
| Income Tax Relating To Components of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss | £100.0K | £100.0K | — |
| Increase Decrease Through Sharebased Payment Transactions | £7.4M | £6.6M | — |
| Intangible Assets Other Than Goodwill | £55.3M | £65.4M | £66.2M |
| Investment Accounted For Using Equity Method | £62.8M | £60.5M | £53.5M |
| Issued Capital | £6.6M | £6.6M | £6.6M |
| Liabilities | £423.0M | £474.3M | £429.6M |
| Net Assets Liabilities | £476.0M | £513.5M | £536.8M |
| Noncurrent Biological Assets | £219.0M | £256.3M | £277.1M |
| Noncurrent Derivative Financial Assets | £0 | £1.2M | £4.9M |
| Noncurrent Derivative Financial Liabilities | £1.0M | £6.3M | £6.2M |
| Noncurrent Investments Other Than Investments Accounted For Using Equity Method | £3.2M | £1.1M | £8.8M |
| Noncurrent Payables | £100.0K | £4.2M | £0 |
| Noncurrent Provisions | £300.0K | £400.0K | £10.3M |
| Noncurrent Recognised Liabilities Defined Benefit Plan | £6.9M | £6.6M | £6.9M |
| Other Comprehensive Income | -£43.1M | -£20.2M | — |
| Other Comprehensive Income Before Tax Cash Flow Hedges | -£1.4M | -£1.6M | — |
| Other Comprehensive Income Before Tax Exchange Differences On Translation | -£35.7M | -£16.0M | — |
| Other Comprehensive Income Before Tax Gains Losses From Investments In Equity Instruments | £0 | -£2.8M | — |
| Other Comprehensive Income Before Tax Hedges of Net Investments In Foreign Operations | -£500.0K | £400.0K | — |
| Other Comprehensive Income Net of Tax Cash Flow Hedges | -£1.2M | -£1.1M | — |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -£41.0M | -£16.6M | — |
| Other Comprehensive Income Net of Tax Gains Losses From Investments In Equity Instruments | — | -£2.8M | — |
| Other Comprehensive Income Net of Tax Hedges of Net Investments In Foreign Operations | -£500.0K | £400.0K | — |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | -£42.7M | -£17.3M | — |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | -£400.0K | -£2.9M | — |
| Other Gains Losses | -£4.2M | -£1.7M | — |
| Other Noncurrent Receivables | £10.3M | £11.8M | £8.2M |
| Payments For Debt Issue Costs | £3.3M | £0 | — |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | £400.0K | £700.0K | — |
| Purchase of Interests In Investments Accounted For Using Equity Method | -£1.3M | £0 | — |
| Reserve of Cash Flow Hedges | -£300.0K | £900.0K | £2.0M |
| Reserve of Exchange Differences On Translation | -£30.8M | £10.5M | £26.7M |
| Retained Earnings | £321.6M | £320.8M | £330.2M |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | £9.1M | £19.1M | — |
| Share Premium | £179.1M | £179.1M | £179.1M |
| Treasury Shares | £100.0K | £100.0K | £100.0K |
Methodology
Every line item above is a fact tagged in GENUS PLC's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (GBP), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.